Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
Loading
Book Value/Share Growth Under PressureDecelerating
Percentile Rank72
5Y CAGR+41.4%
Year-over-Year Change
Year-over-year book value per share growth
5Y CAGR
+41.4%/yr
Long-term compound
Percentile
P72
Within normal range
vs 5Y Ago
5.7x
Strong expansion
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 5.11% |
| Q3 2025 | 14.44% |
| Q2 2025 | 3.41% |
| Q1 2025 | -5.29% |
| Q4 2024 | -4.16% |
| Q3 2024 | 6.21% |
| Q2 2024 | -5.46% |
| Q1 2024 | 13.34% |
| Q4 2023 | 4.43% |
| Q3 2023 | -0.15% |
| Q2 2023 | 1.61% |
| Q1 2023 | 7.08% |
| Q4 2022 | -26.81% |
| Q3 2022 | 1.62% |
| Q2 2022 | 0.89% |
| Q1 2022 | -3.93% |
| Q4 2021 | 0.85% |
| Q3 2021 | 3.07% |
| Q2 2021 | 4.04% |
| Q1 2021 | 2.83% |
| Q4 2020 | 0.90% |
| Q3 2020 | 1.04% |
| Q2 2020 | 8.10% |
| Q1 2020 | -11.15% |
| Q4 2019 | -0.55% |
| Q3 2019 | -15.22% |
| Q2 2019 | 1.19% |
| Q1 2019 | 98.41% |
| Q4 2018 | -19.52% |
| Q3 2018 | 13.20% |
| Q2 2018 | 24.65% |
| Q1 2018 | 16.78% |
| Q4 2017 | -0.43% |
| Q3 2017 | 3.46% |
| Q2 2017 | 2.30% |
| Q1 2017 | 7.33% |
| Q4 2016 | 0.07% |
| Q3 2016 | -6.94% |
| Q2 2016 | 0.65% |
| Q1 2016 | 23.99% |